Related Experiment Video

Updated: Apr 19, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.6K

Targeting and microenvironment-responsive lipid nanocarrier for the enhancement of tumor cell recognition and

Wei Gao1, Tingting Meng, Nianqiu Shi

  • 1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, P. R China.

Advanced Healthcare Materials
|December 19, 2014
PubMed

Insights

This study introduces a novel nanocarrier system (F/TMSP-NLC) that targets solid tumors by utilizing both folate receptors and tumor microenvironment-sensitive polypeptides. This dual-targeting approach enhances drug delivery, leading to improved cancer cell recognition and apoptosis.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Solid tumors present challenges for chemotherapy due to poor drug recognition and penetration.
  • Targeting tumor-specific markers and microenvironment characteristics is crucial for effective cancer therapy.

Purpose of the Study:

  • To develop and evaluate a co-modified nanocarrier (F/TMSP-NLC) for enhanced tumor cell recognition and therapeutic efficacy.
  • To leverage folate receptor (FR) overexpression and matrix metalloproteinase-2 (MMP-2) activity in the tumor microenvironment for targeted drug delivery.

Main Methods:

  • Formulation of folic acid and tumor microenvironment-sensitive polypeptide (TMSP) co-modified lipid-nanocarriers (F/TMSP-NLC).
  • In vitro evaluation of nanocarrier specificity and efficacy in KB, HT-1080, and A549 cancer cell lines.
  • In vivo assessment of F/TMSP-NLC's circulation, tumor accumulation, therapeutic inhibition, and toxicity.

Main Results:

  • F/TMSP-NLC demonstrated enhanced tumor cell recognition and internalization through multivalent interactions.
  • The nanocarriers exhibited a long-circulation effect and high accumulation in tumors.
  • Significant tumor inhibition, increased apoptosis, and negligible toxicity were observed in vivo.

Conclusions:

  • Co-modified nanocarriers (F/TMSP-NLC) represent a promising drug delivery system for improved tumor cell recognition and therapy.
  • Utilizing multiple targets from tumor-stroma interactions offers significant benefits for cancer therapeutic approaches.
Keywords:
cancer cell recognitioncell-penetrating peptidelipid nanocarriersmicroenvironment responsivetarget

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.7K
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.8K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
144
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
133
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K